Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1996 Jan 23;93(2):934–939. doi: 10.1073/pnas.93.2.934

Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines.

P J Murray 1, A Aldovini 1, R A Young 1
PMCID: PMC40162  PMID: 8570663

Abstract

Bacille Calmette-Guérin (BCG) is a live, attenuated strain of Mycobacterium bovis used widely for tuberculosis prophylaxis and bladder cancer immunotherapy, although it has limitations in both contexts. To investigate whether BCG's immunostimulatory properties could be modified, and to gain insight into the interaction between mycobacteria and their hosts, we constructed recombinant BCG strains that secrete functional murine cytokines and studied their properties in mouse models of experimental infection. Cell-mediated immune responses to mycobacterial antigen (purified protein derivative) were assayed using splenocytes from mice inoculated with various BCG recombinants. Antigen-specific proliferation and cytokine release were found to be substantially greater with splenocytes derived from mice injected with cytokine-secreting BCG than with splenocytes from mice injected with BCG lacking cytokines. The most profound effects were induced by BCG secreting interleukin 2, interferon gamma, or granulocyte-macrophage colony-stimulating factor. Thus, cytokine-secreting BCG can enhance immune responses to mycobacterial antigens and may be improved reagents for tuberculosis prophylaxis and cancer immunotherapy.

Full text

PDF
934

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldovini A., Husson R. N., Young R. A. The uraA locus and homologous recombination in Mycobacterium bovis BCG. J Bacteriol. 1993 Nov;175(22):7282–7289. doi: 10.1128/jb.175.22.7282-7289.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aldovini A., Young R. A. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature. 1991 Jun 6;351(6326):479–482. doi: 10.1038/351479a0. [DOI] [PubMed] [Google Scholar]
  3. Bloom B. R., Murray C. J. Tuberculosis: commentary on a reemergent killer. Science. 1992 Aug 21;257(5073):1055–1064. doi: 10.1126/science.257.5073.1055. [DOI] [PubMed] [Google Scholar]
  4. Bretscher P. A. A strategy to improve the efficacy of vaccination against tuberculosis and leprosy. Immunol Today. 1992 Sep;13(9):342–345. doi: 10.1016/0167-5699(92)90168-7. [DOI] [PubMed] [Google Scholar]
  5. Bretscher P. A., Wei G., Menon J. N., Bielefeldt-Ohmann H. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science. 1992 Jul 24;257(5069):539–542. doi: 10.1126/science.1636090. [DOI] [PubMed] [Google Scholar]
  6. Chiu C. P., Moulds C., Coffman R. L., Rennick D., Lee F. Multiple biological activities are expressed by a mouse interleukin 6 cDNA clone isolated from bone marrow stromal cells. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7099–7103. doi: 10.1073/pnas.85.19.7099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Connell N. D., Medina-Acosta E., McMaster W. R., Bloom B. R., Russell D. G. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11473–11477. doi: 10.1073/pnas.90.24.11473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Diederichs K., Boone T., Karplus P. A. Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor. Science. 1991 Dec 20;254(5039):1779–1782. doi: 10.1126/science.1837174. [DOI] [PubMed] [Google Scholar]
  9. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539–3543. doi: 10.1073/pnas.90.8.3539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ealick S. E., Cook W. J., Vijay-Kumar S., Carson M., Nagabhushan T. L., Trotta P. P., Bugg C. E. Three-dimensional structure of recombinant human interferon-gamma. Science. 1991 May 3;252(5006):698–702. doi: 10.1126/science.1902591. [DOI] [PubMed] [Google Scholar]
  11. Fine P. E. The BCG story: lessons from the past and implications for the future. Rev Infect Dis. 1989 Mar-Apr;11 (Suppl 2):S353–S359. doi: 10.1093/clinids/11.supplement_2.s353. [DOI] [PubMed] [Google Scholar]
  12. Flesch I. E., Hess J. H., Huang S., Aguet M., Rothe J., Bluethmann H., Kaufmann S. H. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med. 1995 May 1;181(5):1615–1621. doi: 10.1084/jem.181.5.1615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Forget A., Skamene E., Gros P., Miailhe A. C., Turcotte R. Differences in response among inbred mouse strains to infection with small doses of Mycobacterium bovis BCG. Infect Immun. 1981 Apr;32(1):42–47. doi: 10.1128/iai.32.1.42-47.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gros P., Skamene E., Forget A. Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice. J Immunol. 1981 Dec;127(6):2417–2421. [PubMed] [Google Scholar]
  15. Kong D., Kunimoto D. Y. Secretion of human interleukin 2 by recombinant Mycobacterium bovis BCG. Infect Immun. 1995 Mar;63(3):799–803. doi: 10.1128/iai.63.3.799-803.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lamm D. L. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am. 1992 Aug;19(3):573–580. [PubMed] [Google Scholar]
  17. Langermann S., Palaszynski S., Sadziene A., Stover C. K., Koenig S. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature. 1994 Dec 8;372(6506):552–555. doi: 10.1038/372552a0. [DOI] [PubMed] [Google Scholar]
  18. Luelmo F. BCG vaccination. Am Rev Respir Dis. 1982 Mar;125(3 Pt 2):70–72. doi: 10.1164/arrd.1982.125.3P2.70. [DOI] [PubMed] [Google Scholar]
  19. Matsuo K., Yamaguchi R., Yamazaki A., Tasaka H., Terasaka K., Totsuka M., Kobayashi K., Yukitake H., Yamada T. Establishment of a foreign antigen secretion system in mycobacteria. Infect Immun. 1990 Dec;58(12):4049–4054. doi: 10.1128/iai.58.12.4049-4054.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Morales A., Nickel J. C. Immunotherapy for superficial bladder cancer. A developmental and clinical overview. Urol Clin North Am. 1992 Aug;19(3):549–556. [PubMed] [Google Scholar]
  21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  22. O'Donnell M. A., Aldovini A., Duda R. B., Yang H., Szilvasi A., Young R. A., DeWolf W. C. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun. 1994 Jun;62(6):2508–2514. doi: 10.1128/iai.62.6.2508-2514.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Powers R., Garrett D. S., March C. J., Frieden E. A., Gronenborn A. M., Clore G. M. Three-dimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy. Science. 1992 Jun 19;256(5064):1673–1677. doi: 10.1126/science.256.5064.1673. [DOI] [PubMed] [Google Scholar]
  24. Smith L. J., Redfield C., Boyd J., Lawrence G. M., Edwards R. G., Smith R. A., Dobson C. M. Human interleukin 4. The solution structure of a four-helix bundle protein. J Mol Biol. 1992 Apr 20;224(4):899–904. doi: 10.1016/0022-2836(92)90457-u. [DOI] [PubMed] [Google Scholar]
  25. Stover C. K., de la Cruz V. F., Fuerst T. R., Burlein J. E., Benson L. A., Bennett L. T., Bansal G. P., Young J. F., Lee M. H., Hatfull G. F. New use of BCG for recombinant vaccines. Nature. 1991 Jun 6;351(6326):456–460. doi: 10.1038/351456a0. [DOI] [PubMed] [Google Scholar]
  26. Sudre P., ten Dam G., Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Organ. 1992;70(2):149–159. [PMC free article] [PubMed] [Google Scholar]
  27. Vidal S. M., Malo D., Vogan K., Skamene E., Gros P. Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell. 1993 May 7;73(3):469–485. doi: 10.1016/0092-8674(93)90135-d. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES